Pre Eclampsia                                                                                                     jk"Vhª; xkzeh.
k LokLF; fe’ku
l BP≥140/90 mm Hg on 2 occasions, 4 hours apart                        l Urine proteinuria ≥ traces or ≥ 300 mg/24 hrs sample                                 l Period of gestation>20 weeks
Mild Pre eclampsia                                      Severe Pre eclampsia
l   BP ≥ 140/90 mm Hg                                   l   BP ≥ 160/110 mm Hg
l   Protienuria ≥ traces to 2 + or ≥ 300 mg/24 hrs      l   Proteinuria ≥ 3 + by dipstick or ≥ 5 gm/24 hrs
                                                        l   Headache, epigastric pain, blurring of vision, oliguria, pulmonary odema, thrombocytopenia, IUGR. Creatinine >1.2 mg/dl, serum
                                                            transaminase levels, S LDH>600 IU/L
l   Hospitalize to evaluate and investigate
l   Reassure, no restriction on routine salt intake     l   Urgent hospitalization
l   Rest with limited activity                          l   Start anti hypertensive
l   Start anti hypertensive when DBP ≥ 100 mm Hg        l   Oral Nifedepine 10 mg stat, repeat after 30 minutes if needed OR
l   Tab Alpha Methyl Dopa 250–500 mg 6-8 hourly         l   Inj Labetalol 20 mg IV bolus, repeat 40 mg after 10 minutes if BP not controlled again repeat 80 mg every 10 minutes (max 220 mg) with
    (max 2 gm/day) OR                                       cardiac monitoring
l   Tab Labetalol 100 mg BD (max 2.4 gm/day)
l   Investigate — Hgm, LFT, KFT, S Uric acid,
    S LDH and fundus exam                               l   Continue Tab Nifedepine 10 mg TDS (max 80 mg/day) OR Tab Labetalol 100 mg BD (max 2.4 gm/day)
l   BP and urine output monitoring                      l   Investigate — Hgm, LFT, KFT, S Uric acid, S LDH and fundus exam
                                                        l   Urine output charting
                                                        l   BP Monitoring
l   Continue OPD management in mild disease
l   Continue hospitalization in worsening                     < 24 weeks                       ≥24 -<34 weeks                                     ≥34 weeks                           ≥37 weeks
    hypertension/proteinureia
l   Regular foetal+maternal surveillance (foetal                                                             Treatment should be individualised
    movement count, NST, AFI, wt gain, BP and
    urine output monitoring, weekly Hgm, LFT, KFT,
    S Uric acid and S LDH)                              Foetal salvage difficult             Inj. Betamethasone                 BP controlled                            BP uncontrolled
                                                                                             l 12 mg IM                         l Explain maternal and foetal            l Worsening of clinical /
                                                                                             l Repeat 12 mg                       adverse effect to relatives              biochemical parameters
                                                                                                after 24 hours                  l Regular maternal + foetal              l Signs of foetal compromise
l   Maintain DBP                   If disease severe,                                                                             surveillance
    90-100 mm Hg                   manage as severe
l   No foetal compromise           pre eclampsia
                                                                                                                                     Terminate at 37 weeks
l   Deliver at 38-39 weeks                                                                                               l Terminate pregnancy
                                                                                                                         l Induction of labor as per Bishop score and give Magsulf as in Eclampsia
                                    No role of diuretics
                                                                     For use in medical colleges, district hospitals and FRUs